LGND
Ligand Pharmaceuticals Incorporated · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ligand.com
- Employees(FY) 76
- ISIN US53220K5048
Performance
-0.07%
1W
+7.68%
1M
+16.83%
3M
+50.64%
6M
+20.5%
YTD
+9.03%
1Y
Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Investment Analysis Report: LGND
Overview
In this investment analysis report, we will delve into the financial statements of LGND, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating ...
Technical Analysis of LGND 2024-05-10
Overview:
In analyzing the technical indicators for LGND over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day moving average has been consistently rising, indica...
Recent News & Updates
- 2024-05-13 00:00
- 2024-05-09 20:50
- 2024-05-09 07:26
- 2024-05-08 21:40
- 2024-05-08 01:22
- 2024-05-08 00:19
- 2024-05-07 16:00
Ligand Reports First Quarter 2024 Financial Results(Business Wire)
- 2024-05-07 09:01
- 2024-05-07 07:30
- 2024-05-07 05:40
- 2024-05-07 04:00
Ligand Reports First Quarter 2024 Financial Results(Businesswire)
- 2024-05-06 23:29
- 2024-05-06 19:30
- 2024-05-06 19:30
- 2024-04-23 20:00
LGND: Lowering target price to $73.00(Argus Research)
- 2024-04-23 08:31
- 2024-04-22 20:31
- 2024-04-16 21:55
- 2024-04-08 08:15
- 2024-04-07 20:15
- 2024-04-05 06:00
- 2024-04-03 21:30
- 2024-04-03 21:00
- 2024-04-03 09:00
- 2024-04-02 21:00
- 2024-04-01 06:15
- 2024-03-27 23:30
- 2024-03-26 06:15
- 2024-03-20 21:00
- 2024-03-20 06:00
Page 1 of 6
previousnext